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Objective
To evaluate the cost-effectiveness of adding zoledronic acid or
strontium-89 to standard docetaxel chemotherapy for patients
with castrate-refractory prostate cancer (CRPC).
Patients and methods
Data on resource use and quality of life for 707 patients
collected prospectively in the TRAPEZE 2 9 2 factorial
randomised trial (ISRCTN 12808747) were used to assess the
cost-effectiveness of i) zoledronic acid versus no zoledronic
acid (ZA vs. no ZA), and ii) strontium-89 versus no
strontium-89 (Sr89 vs. no Sr89). Costs were estimated from
the perspective of the National Health Service in the UK and
included expenditures for trial treatments, concomitant
medications, and use of related hospital and primary care
services. Quality-adjusted life-years (QALYs) were calculated
according to patients’ responses to the generic EuroQol EQ-
5D-3L instrument, which evaluates health status. Results are
expressed as incremental cost-effectiveness ratios (ICERs) and
cost-effectiveness acceptability curves.
Results
The per-patient cost for ZA was £12 667, £251 higher than the
equivalent cost in the no ZA group. Patients in the ZA group
had on average 0.03 QALYs more than their counterparts in no
ZA group. The ICER for this comparison was £8 005. Sr89 was
associated with a cost of £13 230, £1365 higher than no Sr89,
and a gain of 0.08 QALYs compared to no Sr89. The ICER for
Sr89 was £16 884. The probabilities of ZA and Sr89 being cost-
effective were 0.64 and 0.60, respectively.
Conclusions
The addition of bone-targeting treatments to standard
chemotherapy led to a small improvement in QALYs for a
modest increase in cost (or cost-savings). ZA and Sr89
resulted in ICERs below conventional willingness-to-pay per
QALY thresholds, suggesting that their addition to
chemotherapy may represent a cost-effective use of resources.
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Introduction
Prostate cancer is one of the commonest types of cancer and
a major health problem around the world. In 2012, >1.1
million men were diagnosed with prostate cancer making this
the second most common male cancer worldwide, accounting
for ~15% of all newly diagnosed male cancers [1]. In the UK,
prostate cancer is the commonest form of cancer, with
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~42 000 men being diagnosed with the disease and almost 11
000 men dying from it annually [2].
Prostate cancer typically presents as local disease, but a
signiﬁcant proportion of patients progress despite initial
treatment. Hormone therapy has been the main treatment for
relapsed prostate cancer [3], leading to responses typically
lasting for 12–24 months. The period after failure of initial
androgen-deprivation therapy is now termed castrate-resistant
prostate cancer (CRPC) [4]. Following two landmark trials,
chemotherapy with docetaxel and prednisolone (DP) is
considered the bedrock of therapy for metastatic CRPC [5,6].
In patients with metastatic disease, the commonest site of
spread is bone. Two treatments approved for bone disease are
zoledronic acid (ZA) [7,8] and strontium-89 (Sr89) [9,10]. A
pre-docetaxel era trial combined chemotherapy with Sr89 in a
small randomised trial and suggested a survival advantage in
patients allocated to Sr89 [11]. ZA is approved on the basis
of reductions in skeletal-related events (SRE), a composite
endpoint including symptomatic fractures, surgeries, and
radiotherapy to bone.
There is considerable uncertainty as to whether the cost of
adding bone-protecting treatments, such as ZA or Sr89, to
standard chemotherapy would be warranted by improved
quality of life (QoL) and reduced use of healthcare resources,
possibly due to fewer SREs. This question is particularly
pertinent as ZA is now available as a generic product, at a
considerably lower price than its branded counterpart.
Given this, we sought to assess the cost effectiveness of
adding bone-protecting treatments to docetaxel chemotherapy
for patients with CRPC, using prospectively collected data
from the TRAPEZE 2 9 2 factorial randomised controlled
trial (ISRCTN 12808747). Two relevant comparisons were
explored in the trial: i) ZA in addition to standard
chemotherapy vs no ZA and ii) Sr89 in addition to standard
chemotherapy vs no Sr89.
Patients and methods
The TRAPEZE trial design is described in detail elsewhere
[12, 13]. Brieﬂy, this was a randomised open label phase III
study using a 2 9 2 factorial design aiming to compare ZA
vs no ZA (stratiﬁed for Sr89) and Sr89 vs no Sr89 (stratiﬁed
for ZA). The trial recruited 757 patients with progressive
metastatic CRPC according to the following eligibility criteria:
age ≥ 18 years, Eastern Cooperative Oncology Group (ECOG)
score ≤2, and adequate haematological, renal, and hepatic
function. Participants were randomised to one of four arms:
i) DP arm: docetaxel 75 mg/m2 3-weekly and oral
prednisolone 10 mg daily for up to 10 cycles; ii) DP+ZA arm:
DP plus ZA 4 mg 3-weekly during chemotherapy then 4-
weekly until disease progression; iii) DP+Sr89 arm: DP for six
cycles, Sr89 150 MBq then further DP up to total of 10
cycles; iv) DP+ZA+Sr89 arm: DP plus both Sr89 and ZA as
above. Ethical approval was received from the Multicentre
Research Ethics Committee and regulatory approval was
granted by the UK Medicines and Healthcare Regulatory
Agency.
The primary outcome of the clinical analysis was clinical
progression-free survival, deﬁned as the number of days from
randomisation to the ﬁrst occurrence of a symptomatic SRE,
pain progression, or death. The main outcome of the cost-
effectiveness analysis is cost per quality-adjusted life-year
(QALY). Responses to EuroQol EQ-5D-3L (a generic
instrument for describing and evaluating health status; each
dimension uses three levels of severity corresponding to no
problems, some problems, and extreme problems), needed for
calculating QALYs and, thereby, cost-effectiveness in this trial
were available for 707 (93%) of the 757 patients. This was a
representative subgroup of the trial patients (Table S1).
Patient characteristics are given in Table 1.
Resource use and cost
Data on healthcare resource use were collected prospectively
through case report forms (CRFs) and patient-completed
questionnaires. Relevant resource use fell under three main
categories: i) trial treatments; ii) concomitant treatments, and
iii) use of other related hospital and primary care services.
The cost of trial treatments was calculated according to
patient-speciﬁc doses and number of treatment cycles
provided, taking into account the cost of drug administration.
The cost of care or medications provided concomitantly with
trial treatment (radiotherapy, abiraterone, cabazitaxel,
mitoxantrone, blood transfusions, additional docetaxel, Sr89,
ZA, and surgical procedures) was obtained by weighting their
respective use recorded in CRFs by unit costs available from
national sources (Table 1) [14–17]. Outpatient appointments,
inpatient stay, and GP visits were drawn from CRFs, while
post-treatment hospital stay and visits were obtained from
patient-completed questionnaires. Questionnaire data were
missing for 126 patients and were imputed using multiple
imputation by chained equations [18].
QoL and QALYs
QALY scores were derived by translating responses to the EQ-
5D-3L health status instrument [19] into preference-based
(utility) scores using a standard value set [20]. The EQ-5D-3L
was collected 3-weekly during treatment, then monthly for 3
months, and 3-monthly until death. QALYs were calculated as
the area under the curve connecting utility scores available at
different time points. For patients who were known to have
died, a utility of zero was assigned on the date of death [21].
For patients still alive at the time of analysis, their last known
EQ-5D-3L score was carried forward to the date last seen.
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Cost-effectiveness analysis
Analyses were conducted from the perspective of the NHS in
the UK. Consistent with recommendations, costs and beneﬁts
accruing beyond 12 months were discounted at a rate of 3.5%
per year [22]. A total cost and a total number of QALYs were
calculated for each patient, with 95% CIs around mean values
obtained through 1000 bias-corrected and accelerated (BCa)
bootstrap replications [23,24]. Given the short expected
survival time of patients with metastatic CRPC and the long-
term follow-up of patients in the trial, lifetime costs and
effects were largely observed and so extrapolation beyond the
trial was unnecessary. In the comparison between ZA and no
ZA, the main analysis was based on the fact that, as of 2013,
ZA has been available as a generic product, at a price
signiﬁcantly lower than its branded counterparts. Additional
analyses were conducted on the basis of the proprietary
product.
Differences in mean total costs and QALYs between the
compared options were presented as incremental cost-
effectiveness ratios (ICERs), a measure reﬂecting the
additional cost associated with a gain of an additional QALY
[25]. To account for uncertainty in the results, nonparametric
bootstrapping was used to replicate the joint distribution of
the differences in cost and QALYs [26]. This generated 5000
paired estimates of incremental costs and QALYs, which were
subsequently used to derive cost-effectiveness acceptability
curves [27]. Cost-effectiveness acceptability curves show the
probability of each option being cost-effective across a range
of possible values of willingness to pay (ceiling ratio) for an
additional QALY [28]. The impact of alternative assumptions
and uncertain values on the results were explored in
additional sensitivity analyses.
Results
Comparison of ZA vs no ZA
Cost by resource use category, total costs and total QALYs
for the comparison between ZA and no ZA are given in
(Table 2). The most substantial difference in costs was due to
the use of ZA itself provided as protocol and follow-up
treatment in the ZA group. With the exception of ZA,
patients in the ZA group presented lower use of additional
care and medications. Notably, there were differences in the
use of radiotherapy and surgery, reﬂective of the fact that
patients in the ZA group had fewer SREs. The difference in
total costs between ZA and no ZA was £251 (BCa 95% CI:
£1099 to £1602); this difference was contingent on the
acquisition cost of ZA. In relation to health beneﬁts, patients
in the ZA group had an average of 0.91 QALYs, reﬂecting a
gain of 0.03 QALYs (BCa 95% CI: –0.07 to 0.13) over their
counterparts in the no ZA group.
Table 1 Unit cost prices and sources.
Item Cost, £ Source
Docetaxel 155 for 1 mL vial (20 mg) British National Formulary [14]
Prednisolone 0.64/day British National Formulary [14]
ZA 58 for 4mg NHS Commercial Medicines Unit [17]
Sr89 1710 per fraction of 150 mBq Nuclear Medicine Department, University
Hospital Birmingham.
Abiraterone 98/day British National Formulary [14]
Cabazitaxel 3696/cycle British National Formulary [14]
Mitoxantrone 100/cycle British National Formulary [14]
Radiotherapy 813 cost of radiotherapy
preparation plus
118 cost of radiotherapy fraction
NHS Reference Costs [16]
Blood 123/unit plus i.v. cannula (£1)
and blood giving set (£4)
NHS Blood and Transplant
Administration of DP, ZA
(standalone), mitoxantrone
245 NHS Reference Cost [16]
Administration cabazitaxel 144 NHS Reference Cost [16]
Administration of Sr89 443 Nuclear Medicine Department, University
Hospital Birmingham
Blood transfusion 172 NHS Reference Cost [16]
Decompression for spinal cord compression 9573 NHS Reference Cost [16]
Laminectomy 6893 NHS Reference Cost [16]
Intramedullary nailing 4995 NHS Reference Cost [16]
Hip replacement 8038 NHS Reference Cost [16]
Fracture 3888 NHS Reference Cost [16]
Spinal cord compression 7816 NHS Reference Cost [16]
Inpatient stay 680 NHS Reference Cost [16]
Outpatient appointment 135 Personal Social Services Research Unit [15]
GP consultation 63 Personal Social Services Research Unit [15]
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Combining differences in costs and QALYs resulted in an
ICER of £8005 per QALY. At the commonly cited lower
willingness-to-pay ratio of £20 000 per QALY in the UK [22,
29–33], the probability of ZA being cost-effective is 0.64
(Fig. 1). For prices of ZA between £0 and £31, the total per-
patient cost of ZA is lower than that of no ZA and, given the
fact that ZA is associated with a slight increase in QALYs, this
treatment option dominates its comparator. For prices between
£31 and £98, ZA results in ICERs up to £20 000 per QALY,
and it is thus cost-effective at this willingness-to-pay value.
Most of the alternative assumptions explored in additional
sensitivity analyses (e.g. different prices of concomitant
medications, no discounting etc.) had a small, proportional
effect on the additional cost and beneﬁts of each treatment
option, and, thus, they had a minimal impact on the resulting
ICER (Table S2). The only exception was the adjustment of
QALYs for baseline imbalances in EQ-5D-3L scores, which
resulted in a very small, non-signiﬁcant difference in QALYs
in favour of no ZA (0.0006 QALYs, 95% CI: –0.096 to 0.094).
For ZA prices up to £28, ZA is less costly and less effective,
but overall more cost-effective than no ZA (at £20 000 per
QALY foregone), and it is more costly and less effective (i.e.
dominated) above this price (Fig. S1).
Comparison of Sr89 vs no Sr89
The most prominent difference in mean costs between the Sr89
and no Sr89 groups was due to the use of Sr89 itself. Apart from
the higher cost for Sr89, the Sr89 group was associated with
greater cost for docetaxel and ZA given as protocol treatments,
higher cost for cabazitaxel and docetaxel provided as concomitant
medications, and increased cost due to surgeries. On the other
hand, the Sr89 group was associated with fewer radiotherapies,
lower use of abiraterone, ZA, and Sr89 as concomitant
medications, and fewer inpatient days, outpatient appointments,
and GP visits (Table 3). The analysis showed mean total costs per
person of £13 230 and £11 865 for Sr89 and no Sr89 respectively,
resulting in a mean difference of £1365 (BCa 95% CI: –£12 to
£2742). For the comparison between Sr89 vs no Sr89, patients
who received Sr89 showed a gain of 0.08 QALYs (BCa 95% CI: –
0.019 to 0.181) over those in the no Sr89 group.
Table 2 Mean per-patient cost and QALYs for ZA vs no ZA.
ZA (n = 350) No ZA (n = 357) Difference (ZA vs no ZA)
Mean (SD) Mean (SD) Mean difference Lower 95% CI* Upper 95% CI*
Trial treatment, £
DP 2502 (760) 2441 (749) 60 49 169
ZA 346 (151) 0 346 330 361
Sr89 769 (1033) 724 (1018) 45 107 197
ZA as follow-up treatment 837 (1358) 3 (48) 834 692 977
Concomitant medications and treatments, £
Radiotherapy 764 (1093) 1021 (1264) 257 429 85
Abiraterone 1811 (4198) 2150 (4478) 339 993 316
ZA as concomitant medication 235 (801) 101 (492) 134 36 230
Sr89 as concomitant medication 98 (476) 132 (539) 34 109 41
Blood units 23 (150) 19 (125) 4 16 24
Cabazitaxel 301 (1710) 293 (2230) 8 288 304
Docetaxel as concomitant medication 372 (1543) 433 (2049) 61 338 216
Mitoxantrone 51 (245) 26 (179) 25 6 56
Surgery 116 (988) 377 (1974) 261 495 27
Outpatient appointments and inpatient stay, £
Hospital outpatient appointment 672 (1015) 591 (804) 81 51 213
Hospital inpatient stay 3494 (6216) 3786 (6562) 292 1217 632
GP appointments 278 (319) 319 (384) 42 95 12
Total Cost, £ 12667 (8795) 12417 (9433) 251 1099 1602
Total QALYs 0.908 (0.683) 0.876 (0.693) 0.031 0.07 0.133
*Obtained using the bias corrected and accelerated bootstrap method (1000 replications).
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being cost-effective at different values of willingness to pay per additional
QALY.
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Overall, Sr89 was associated with a higher total per-patient
cost and a greater mean number of QALYs compared to no
Sr89. Given these differences, the point estimate ICER for
Sr89 was calculated at £16 884 per additional QALY. At a
willingness-to-pay value of £20 000 for an additional QALY,
the probability that Sr89 is cost-effective is 0.6 (Fig. 2). The
ICER for Sr89 remains below £20 000 per QALY for prices of
Sr89 up to £2120.
Most of the alternative scenarios explored in sensitivity
analyses had a limited impact on the magnitude of the results
and did not change the baseline conclusion for this
comparison (Table S2). An exception was the analysis using
different prices for Sr89: a lower price of Sr89 gives an ICER
of £13 182 per QALY, whereas a higher price resulted in an
ICER of £20 585 per QALY.
Discussion
The present study uses patient-level data collected in the
TRAPEZE trial to determine whether the addition of ZA or
Sr89 bone-protecting therapies to standard chemotherapy
represents a cost-effective use of healthcare resources.
The comparison between ZA and no ZA showed ZA to be
associated with a small additional cost for a slight
improvement in QALYs. This additional cost was relatively
modest, owing to the low additional cost for ZA and the fact
that this cost was largely counterbalanced by reduced use of
other healthcare resources (e.g. fewer radiotherapies and
surgeries). Prevention of serious events such as fracture,
surgery, and cord compression is seen as a desirable outcome
for the NHS [34]; therefore, a predictable, outpatient therapy
with modest net acquisition costs may be attractive to
providers if it prevents emergency, unpredictable visits. In the
likely case that the NHS pays less than £31 for a dose of ZA,
ZA is the dominant option, being less costly and more
effective than no ZA.
The magnitude of the additional cost in the ZA group is to a
great extent dependent on the acquisition cost of ZA. Since
2013, ZA is available as a generic product, at a price
Table 3 Mean per-patient cost and QALYs for Sr89 vs no Sr89.
Sr89 (n = 350) No Sr89 (n = 357) Difference (Sr89 vs no Sr89)
Mean (SD) Mean (SD) Mean difference Lower 95% CI* Upper 95% CI*
Trial treatment, £
DP 2497 (738) 2445 (771) 52 61 165
ZA 174 (203) 168 (203) 6 23 35
Sr89 1507 (988) 0 1507 1407 1608
ZA as follow-up treatment 391 (965) 440 (1114) 49 197 100
Concomitant medications and treatments, £
Radiotherapy 803 (1033) 983 (1318) 180 349 11
Abiraterone 1905 (4279) 2058 (4408) 153 814 508
ZA as concomitant medication 148 (625) 187 (704) 39 139 61
Sr89 as concomitant medication 110 (527) 120 (492) 9 85 66
Blood units 21 (150) 21 (124) 0 20 21
Cabazitaxel 375 (2192) 221 (1765) 154 134 443
Docetaxel as concomitant medication 415 (2057) 390 (1545) 25 233 283
Mitoxantrone 39 (218) 39 (211) 0 32 31
Surgery 325 (1954) 172 (1064) 153 84 390
Outpatient appointments and inpatient stay, £
Hospital outpatient appointment 609 (889) 653 (940) 44 178 89
Hospital inpatient stay 3630 (6294) 3653 (6491) 23 950 903
GP appointments 281 (350) 316 (357) 35 86 16
Total Cost, £ 13230 (9105) 11865 (9091) 1365 12 2742
Total QALYs 0.933 (0.725) 0.852 (0.648) 0.081 0.019 0.181
*Obtained using the bias corrected and accelerated bootstrap method (1000 replications).
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Cost-effectiveness of ZA and Sr89
markedly lower than the equivalent proprietary products
(Zometa and Aclasta). Given the average price paid by
NHS hospitals for ZA in the UK, the additional cost of ZA
was low, at £251, resulting in an attractive ICER of about
£8000 per QALY. In the likely case that the NHS pays less
than £31 for a dose of ZA, ZA is the dominant option (i.e.
less costly and more effective, in terms of QALYs, than no
ZA).
The Sr89 group was associated with an increase in cost and
an improvement in QALYs, which translated into an ICER of
£16 900 per QALY. However, these results will need to be
seen in light of the fact that several new treatments licenced
in the last few years have now emerged, including
abiraterone, enzalutamide, cabazitaxel and, of particular
relevance to this study, radium-223.
For both the comparison between ZA vs no ZA and Sr89 vs
no Sr89, the calculated CIs of the differences in QALYs
overlapped zero, suggesting that the observed improvements
in QALYs are not statistically signiﬁcant. However, given the
fact that the TRAPEZE trial was not powered to detect
statistically signiﬁcant differences in QALYs, the observed
results should not be interpreted as conclusive evidence of
presence or absence of a signiﬁcant difference. Consistent
with recommendations, the interpretation of the results is
based on the outcome of the ICERs and the uncertainty
surrounding them [25,35].
To our knowledge, this is the ﬁrst economic evaluation based
on prospectively collected data aiming to assess the cost-
effectiveness of providing patients with CRPC with ZA and
Sr89 in addition to standard chemotherapy. A major strength
of the present study lies in the fact that data were obtained
from a large pragmatic randomised controlled trial. In line
with guidance in conducting economic evaluations, costs were
estimated by weighting prospectively collected patient-level
resource use by unit costs drawn from national sources,
health beneﬁts were measured using a widely used preference-
based measure, and analyses of the collected data were
performed using recommended statistical methods [24,36–38].
While the analysis was carried out from the perspective of the
NHS in the UK, the fact that the care pathway for CRPC is
similar across developed countries makes the ﬁndings
pertinent to other healthcare systems.
Despite this, the study presents certain methodological
challenges. First, ZA appeared to have a minimal effect on
QoL, which did not tally with the marked change in the
number and severity of SREs. Given that events such as pain
leading to radiotherapy, fracture, and spinal cord compression
must certainly impair QoL, it is possible that temporary
drops in QoL due to unpredictable SREs may have not been
captured. This may be explained by the fact that the EQ-5D-
3L forms are typically completed at predetermined points
after randomisation, which are likely to fall either before
SREs or after problems are resolved. Failure to capture
temporary declines in QoL due to SREs indirectly penalises
groups associated with fewer SREs, in this case, the ZA
group. Secondly, similarly to all trials, prospectively collected
data are bound to be incomplete. In particular, ﬁnal terminal
phase SREs, resource use and beneﬁts are difﬁcult to capture,
as patients are generally less likely to attend trial clinics in
that period [39,40]. Last, while the trial protocol made
provisions for six cycles of docetaxel chemotherapy plus an
additional four cycles ‘off study’, the National Institute for
Health and Care Excellence (NICE) in the UK recommended
that up to 10 cycles of docetaxel chemotherapy should be
administered in one treatment block. Given the intended
pragmatic nature of this trial, adopting the NICE
recommendation ensured that treatment arms reﬂected the
true ‘standard of care’. Owing to the fact that docetaxel
chemotherapy was provided across all treatment groups, this
change is not expected to impact on a particular treatment
group over another.
Further research in the area would be valuable. Despite the
patient-level evidence obtained from the trial, more detailed
estimates of QoL associated with SREs and use of healthcare
resources would be useful. The latter is typically accessible
via the Hospital Episode Statistics (HES) database, which
contains details of all admissions, outpatient appointments,
and emergency attendances at NHS hospitals [41]. Further
analyses using HES will give the opportunity to corroborate
the present study ﬁndings. In addition, it would be
interesting to obtain insights into the clinical effectiveness
and cost-effectiveness of both ZA and Sr89 as compared to
neither treatment. While the TRAPEZE trial was not
designed to investigate such comparisons, this could be
pursued in a future study speciﬁcally designed to assess the
particular treatment options.
In conclusion, the present ﬁndings suggest that the
addition of bone-targeting treatments to standard
chemotherapy lead to a small positive change in QALYs
for a small additional cost (or cost-savings), resulting in an
ICER below the threshold of £20 000 per QALY. These
cost-effectiveness results, coupled with the treatments’
positive impact on SRE prevention, suggest that
supplementation of chemotherapy with bone-protecting
treatments is likely to represent a cost-effective use of the
available healthcare resources.
Acknowledgements
We would like to acknowledge the clinicians, research teams
and patients who participated in the trial. Thanks also must
go to the trial management team for the collecting and entry
of trial data prior to analysis, and to Dr Jenny Barnwell, the
trial management team leader for her advice during the trial
and for review of this manuscript.
6
© 2016 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Andronis et al.
Conﬂicts of Interest
Nicholas James reports consultancy work and lecture fees
from Sanoﬁ Aventis Pharma and Novartis (directly related)
and consultancy work and lecture fees from Bayer, Amgen,
Janssen, Astellas, Afﬁnity (related to prostate cancer but not
drugs in this study). Ann Pope reports grants payable to
investigation sites from Sanoﬁ Aventis on the recruitment of
patients, provision of Zometa during the phase II trial and
later a trial speciﬁc discount for sites the purchase of trial
drug from Novartis and a trial speciﬁc discount for sites from
GE Healthcare for the purchase of trial drug, during the
conduct of the study. Chris Parker reports personal fees from
Bayer, BNIT, Astellas, Janssen, Sanoﬁ Aventis and Takeda,
outside the submitted work. Andrew Stanley reports that
TEVA supported his attendance at ESMO, he received
personal fees from CALGENE, and AMGEN supported part
of his attendance at BOPA, outside the submitted work. Janet
Brown reports personal fees and non-ﬁnancial support from
Novartis, outside the submitted work. Lucinda Billingham
reports personal fees from Eli Lilly, personal fees from Pﬁzer,
outside the submitted work. Lazaros Andronis, Ilias Goranitis,
Sharon Beesley, Alison Birtle, Stuart Collins, Duncan
McLaren, Joe O’Sullivan, Emilio Porﬁri, John Staffurth, James
Wylie, Prabir Chakraborti, Syed Hussain, Martin Russell,
Daren Barton, Adam Daunton and Sarah Pirrie report no
conﬂicts of interest.
References
1 Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012: Estimated
Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon,
France: International Agency for Research on Cancer, 2014 Available at:
http://globocan.iarc.fr/Default.aspx. Accessed June 2016
2 Cancer Research UK. Prostate cancer key facts, 2014. Available at: http://
publications.cancerresearchuk.org/downloads/Product/
CS_KF_PROSTATE.pdf. Accessed October 2014.
3 Huggins C, Hodges CV. Studies on prostatic cancer: I The effect of
castration, of estrogen and of androgen injection on serum phosphatases
in metastatic carcinoma of the prostate. J Urol. Jul 2002;168:9–12.
4 Scher HI, Halabi S, Tannock I et al. Design and end points of clinical
trials for patients with progressive prostate cancer and castrate levels of
testosterone: recommendations of the prostate cancer clinical trials
working group. J Clin Oncol 2008; 26: 1148–59
5 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med
2004; 351: 1502–12
6 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine
compared with mitoxantrone and prednisone for advanced refractory
prostate cancer. N Engl J Med 2004; 351: 1513–20
7 Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled
trial of zoledronic acid in patients with hormone-refractory metastatic
prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68
8 Saad F, Gleason DM, Murray R et al. Long-term efﬁcacy of zoledronic
acid for the prevention of skeletal complications in patients with
metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;
96: 879–82
9 Bolger JJ, Dearnaley DP, Kirk D et al. Strontium-89 (Metastron) versus
external beam radiotherapy in patients with painful bone metastases
secondary to prostatic cancer: preliminary report of a multicenter trial.
UK Metastron Investigators Group. Semin Oncol 1993; 20(Suppl. 2):
32–3
10 Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects
of strontium-89 and external beam radiotherapy in metastatic prostate
cancer. Radiother Oncol 1994; 31: 33–40
11 Lennox AS, Osman LM, Reiter E et al. Cost effectiveness of computer
tailored and non-tailored smoking cessation letters in general practice:
randomised controlled trial. BMJ 2001; 322: 1396
12 James ND, Pirrie S, Pope A et al. TRAPEZE: a randomised controlled
trial of the clinical and cost effectiveness of chemotherapy with zoledronic
acid, strontium-89 or both, in men with bony metastatic castrate
refractory prostate cancer. Health Technol Assess 2016. In press.
13 James ND, Pirrie S, Barton D, Billingham L. Clinical outcomes in
patients with castrate-refractory prostate cancer (CRPC) metastatic to
bone randomized in the factorial TRAPEZE trial to docetaxel (D) with
strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN
12808747). J Clin Oncol 2013;31(Suppl.): abstract LBA5000
14 British Medical Association. British National Formulary, London: BNA
and RPS: 2014
15 Curtis L.Unit Cost of Health and Social Care 2014. Personal Social
Services Research Unit. Available at: http://www.pssru.ac.uk/project-pages/
unit-costs/2014/. Accessed July 2014
16 Department of Health. National schedule of reference costs 2013 to 2014
Available at: https://www.gov.uk/government/publications/nhs-reference-
costs-2013-to-2014. Accessed July 2014
17 NHS Commercial Medicines Unit. Electronic market information tool.
2014 Available at: http://cmu.dh.gov.uk/electronic-market-information-
tool-emit/. Accessed October 2014
18 Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional
speciﬁcation versus multivariate normal imputation. Am J Epidemiol 2010;
171: 624–32
19 Brooks R. EuroQol: the current state of play. Health Policy 1996; 37:
53–72
20 Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;
35: 1095–108
21 Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of
quality-of-life and survival data in health technology assessment. Health
Technol Assess 1999; 3: 1–152
22 National Institute for Health and Care Excellence (NICE). Guide to the
methods of technology appraisal 2013 Available at: http://
www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-
methods-of-technology-appraisal-2013-pdf. Accessed September 2014
23 Barber J, Thompson S. Analysis of cost data in randomized trials: an
application of the non-parametric bootstrap. Stats Med 2000; 19: 3219–36
24 Glick HA, Jalpa DA, Sonnad SS, Polsky D. Economic Evaluation in
Clinical Trials, Oxford: Oxford University Press: 2007
25 Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL.
Methods for the Economic Evaluation of Health Care Programmes, Oxford:
Oxford University Press: 2005
26 Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and
presenting results of cost-effectiveness analyses. Expert Rev Pharmacoecon
Outcomes Res 2001; 1: 25–36
27 van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-
ratios alongside a clinical trial. Health Econ 1994; 3: 309–19
28 Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions:
the role of the cost-effectiveness acceptability curve (CEAC), the cost-
effectiveness acceptability frontier (CEAF), and the expected value of
perfection information (EVPI). Value Health 2008; 11: 886–97
© 2016 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 7
Cost-effectiveness of ZA and Sr89
29 Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and
what other factors inﬂuence its decisions? A binary choice analysis. Health
Econ 2004; 13: 437–52
30 Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new
technology have to be to warrant adoption and utilization? Tentative
guidelines for using clinical and economic evaluations. CMAJ 1992; 146:
473–81
31 Pritchard C. Overseas approaches to decision making. In: Towse A,
Pritchard C, Devlin N, eds., Cost-Effectiveness Thresholds. Economic and
Ethical. Issues. London: King’s Fund and Ofﬁce of Health Economics,
2002
32 Weinstein MC. How much are Americans willing to pay for a quality-
adjusted life year? Med Care 2008; 46: 343–5
33 Bae YH, Mullins CD. Do value thresholds for oncology drugs differ from
nononcology drugs? J Manag Care Pharm 2014; 20: 1086–92
34 Department of Health. NHS 2010–2015: from good to great. Preventative,
people-centred, productive. 2009 Available at: https://
www.gov.uk/government/uploads/system/uploads/attachment_data/ﬁle/
228885/7775.pdf. Accessed February 2015
35 Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied
methods of cost-effectiveness analysis in healthcare, Oxford: Oxford
University Press: 2011
36 Ramsey S, Willke R, Briggs A et al. Good research practices for cost-
effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task
Force Report. Value Health 2005; 8: 521–33
37 Briggs A, Clark T, Wolstenholme J, Clarke P. Missing. presumed at
random: cost-analysis of incomplete data. Health Econ 2003; 12:
377–92
38 Andronis L, Barton P, Bryan S. Sensitivity analysis in economic
evaluation: an audit of NICE current practice and a review of its use and
value in decision-making. Health Technol Assess 2009;13: iii, ix–xi, 1–61
39 McMillan SC, Weitzner MA. Methodologic issues in collecting data from
debilitated patients with cancer near the end of life. Oncol Nurs Forum
2003; 30: 123–9
40 Molenberghs G, Kenward M. Missing Data in Clinical Studies, Vol. 61,
Hoboken, New Jersey: John Wiley & Sons: 2007
41 Health and Social Care Information Centre. Hospital episode statistics
database 2015. Available at: http://www.hscic.gov.uk/hes. Accessed May
2015.
Correspondence: Lazaros Andronis, Health Economics Unit,
School of Health and Population Sciences, College of Medical
and Dental Sciences, University of Birmingham, Birmingham
B15 2TT, UK.
e-mail: l.andronis@bham.ac.uk
Abbreviations: BCa, bias-corrected and accelerated; CRF, case
report form; CRPC, castrate-refractory prostate cancer; DP,
docetaxel and prednisolone; ECOG, Eastern Cooperative
Oncology Group; HES, Hospital Episode Statistics; ICER,
incremental cost-effectiveness ratio; NICE, National Institute
for Health and Care Excellence; QALY, quality-adjusted life-
year; QoL, quality of life; SRE, skeletal-related events; ZA,
zoledronic acid.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Graph showing ICER for ZA vs no ZA at different
prices of ZA, after adjusting for baseline imbalances in
EQ-5D-3L.
Table S1. Summary characteristics of participants included in
the economic evaluation (n = 707) and all study participants
(n = 757).
Table S2. Results of sensitivity analyses for ZA vs no ZA and
Sr89 vs no Sr89.
8
© 2016 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International
Andronis et al.
